Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GS1-144 in Healthy Postmenopausal Women
NCT06983925Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GS1-144 in vasomotor symptoms (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Peak Plasma Concentration, Area under the blood concentration-time curve from 0 to last quantifiable time and 4 more. Started Apr 2025; status: completed.
02
Drugs
GS1-144
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT06983925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06983925.